News

Please download and read our company press releases below.

17 June 2010

Inotek Pharmaceuticals Initiates Multiple-Dose Phase 2 Clinical Trial of INO-8875 in Patients with Glaucoma

10 June 2010

Inotek Pharmaceuticals Closes $18 Million Preferred Stock Financing

4 May 2010

Inotek Pharmaceuticals Presents Preclinical Data at ARVO Confirming that INO-8875 Lowers IOP by Increasing Outflow through the Trabecular Meshwork

27 April 2010

Inotek Pharmaceuticals to Present New Preclinical Data on Novel Mechanism of Action for Lead Glaucoma Candidate INO-8875

4 March 2010	Inotek Pharmaceuticals to Present at the Cowen 30th Annual Health Care Conference on Thursday, March 11
25 June 2009	Inotek Pharmaceuticals' Novel Glaucoma Candidate, INO-8875, Significantly Reduces Intraocular Pressure in Phase 1/2 Study
6 May 2009	Inotek Pharmaceuticals Presents Preclinical Data in Support of Novel Glaucoma Candidate, INO-8875 at ARVO
28 Apr 2009	Inotek Pharmaceuticals' Novel Glaucoma Candidate, INO-8875, Selected for Presentation at the ARVO 2009 Annual Meeting
13 Nov 2008	Patents Issue for Inotek Pharmaceuticals’ Lead Clinical Candidates in Glaucoma and Contrast-Induced Nephropathy
1 Oct 2008	Inotek Appoints Paul G. Howes as President and CEO
18 Jun 2008	Inotek Commences Phase 1 Trial in Glaucoma with Selective Adenosine 1 (A1) Agonist